Table 5.

Adverse events in both treatment groups for a 6-month study period.

Adverse event	Aranesp	Eprex	P-value *
Vascular access thrombosis	0 (0%)	3 (5%)	0.064
High blood pressure	6 (9%)	7 (11.7%)	0.615
Stroke	0 (0%)	1 (1.7%)	0.289
Myocardial infarction	1 (1.5%)	1 (1.7%)	0.937
Vomiting	2 (3%)	3 (5%)	0.560
Nausea	4 (6%)	5 (8.3)	0.604
Diarrhea	1 (1.5%)	0 (0%)	0.342
Edema	2 (3%)	1 (1.7%)	0.625
Pain at the site of the injection	7 (10.4)	9 (15%)	0.440

^*P-values were obtained by a chi-square test.